Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 5,391 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Random Match Clear all
Completed Phase 3 Interventional Results available

Telotristat Etiprate for Carcinoid Syndrome Therapy

NCT02063659
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Telotristat etiprate, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Stanford, California • Orlando, Florida • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 26, 2026, 5:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers

NCT00653822
View directory record Official record
Conditions
Pharmacokinetics of Alefacept
Interventions
alefacept, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
20 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 26, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain

NCT01452529
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Hydrocodone bitartrate q24h film-coated tablets, Placebo to match hydrocodone bitartrate q24h tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 26, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease

NCT02207829
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium, Umeclidinium matching placebo, Tiotropium, Tiotropium matching placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,017 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 26, 2026, 5:07 AM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease

NCT01397539
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BIIB037, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
55 Years to 85 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Delray Beach, Florida • Orlando, Florida • Beachwood, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 26, 2026, 5:07 AM EDT
Completed Phase 4 Interventional

To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses

NCT00648973
View directory record Official record
Conditions
Nasal Congestion
Interventions
Diphenhydramine 50 mg, Diphenhydramine 25 mg, Pseudoephedrine 120 mg
Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
Austin, Texas • Dallas, Texas • Kerrville, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Oct 26, 2026, 5:07 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants

NCT04082741
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986318, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 26, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis

NCT02844777
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Placebo, 5% VDA-1102, 10% VDA-1102
Drug
Lead sponsor
Vidac Pharma
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 26, 2026, 5:07 AM EDT
Completed Not applicable Interventional

Ashwagandha for Nighttime Waking

NCT07151261
View directory record Official record
Conditions
Disturbed Sleep
Interventions
Ashwagandha, Placebo
Dietary Supplement · Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 26, 2026, 5:07 AM EDT
Completed Phase 2 Interventional

A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

NCT01594983
View directory record Official record
Conditions
Non Familial Chylocmicronemia Syndrome (Non-FCS)
Interventions
LCQ908, Fenofibrate, Fish Oil, Placebo of LCQ908, Placebo of fenofibrate, Placebo of fish oil
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Muscle Shoals, Alabama • Glendale, Arizona • Encinitas, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 26, 2026, 5:07 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

ARREST PAD (Peripheral Arterial Disease)

NCT00153166
View directory record Official record
Conditions
Arterial Occlusive Disease, Intermittent Claudication, Insulin Resistance
Interventions
atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, placebo/placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 26, 2026, 5:07 AM EDT
Terminated Phase 2 Interventional Results available

Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

NCT06784973
View directory record Official record
Conditions
RSV Infection
Interventions
Obeldesivir, Obeldesivir Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 5 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
41
States / cities
Birmingham, Alabama • Oneonta, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 26, 2026, 5:07 AM EDT
Recruiting Phase 3 Interventional

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

NCT07351045
View directory record Official record
Conditions
Obesity or Overweight
Interventions
Placebo, Enicepatide
Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
44
States / cities
Anniston, Alabama • Birmingham, Alabama • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 5:07 AM EDT
Not yet recruiting Not applicable Interventional

PREPUP: A Randomized Trial of Bonvadis® Versus Collagenase Ointment in Diabetic Foot Ulcers

NCT07779239
View directory record Official record
Conditions
Diabetic Foot Ulcers (DFUs)
Interventions
Bonvadis® (NWBOT), Clostridial Collagenase Ointment
Device
Lead sponsor
Oneness Biotech Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
North Port, Florida • Palm Coast, Florida • South Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 26, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00712673
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 26, 2026, 5:07 AM EDT
Completed Not applicable Interventional

Notched Noise Therapy for Suppression of Tinnitus

NCT04661995
View directory record Official record
Conditions
Tinnitus, Notched Noise Therapy
Interventions
Hearing Aid and Notched Noise Therapy, Hearing Aid and Broadband Noise, Hearing Aid
Combination Product · Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 26, 2026, 5:07 AM EDT
Not yet recruiting Not applicable Interventional

Dynamic, Real-world Learning, Innovative Mobility, and Versatile Exploration (DRIVE): Evaluating a Dose-matched Developmental Powered Mobility Intervention for Young Children With Cerebral Palsy

NCT07876219
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Permobil Explorer Mini, MORE-PT
Device · Other
Lead sponsor
University of Washington
Other
Eligibility
12 Months to 33 Months
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Grand Rapids, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 26, 2026, 5:07 AM EDT
Terminated Phase 3 Interventional Results available

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

NCT05665088
View directory record Official record
Conditions
Agitation, Dementia
Interventions
BXCL501, Matching Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
65 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Los Alamitos, California • Daytona Beach, Florida • Maitland, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 26, 2026, 5:07 AM EDT
Recruiting Phase 3 Interventional

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

NCT07177339
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Depemokimab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 75 Years
Enrollment
1,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
42
States / cities
Newport Beach, California • Lakewood, Colorado • Brandon, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 26, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue

NCT03423173
View directory record Official record
Conditions
Dengue Fever
Interventions
TAK-003, Placebo
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
923 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
14
States / cities
Huntsville, Alabama • Anaheim, California • Boise, Idaho + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 26, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

NCT02273973
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Placebo, Taselisib
Drug · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Santa Ana, California • Boston, Massachusetts • Basking Ridge, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 26, 2026, 5:07 AM EDT
Completed Early Phase 1 Interventional

Propensity to Develop Plasticity in the Parieto-Motor Networks in Dystonia From the Perspective of Abnormal High-Order Motor Processing

NCT02504905
View directory record Official record
Conditions
Writer's Cramp, Healthy Volunteers, Cervical Dystonia
Interventions
TMS
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 26, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection

NCT03361956
View directory record Official record
Conditions
Hepatitis B
Interventions
JNJ-56136379, Placebo, NA (ETV or TDF)
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
18 Years to 70 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Bakersfield, California • Orlando, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 26, 2026, 5:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Xla1 Christensenella Minuta, Phase I, Randomized, Partially Placebo-controlled Double-blind Protocol, Evaluating Safety, Tolerability and Impact on the Gut Microbiota in Healthy Volunteers, Overweight and Obese Adults

NCT04663139
View directory record Official record
Conditions
Obesity, Metabolic Disease
Interventions
Xla1, Placebo
Drug
Lead sponsor
YSOPIA Bioscience
Industry
Eligibility
19 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 26, 2026, 5:07 AM EDT